Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children
- PMID: 25869891
- DOI: 10.1016/j.vaccine.2015.04.011
Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children
Abstract
Background: Immunological studies have indicated that the effectiveness of AS03 adjuvanted monovalent influenza A(H1N1)pdm09 vaccine (Pandemrix) may be of longer duration than what is seen for non-adjuvanted seasonal influenza vaccines. Sixty-nine percent of children 6 months-18 years of age in Stockholm County received at least one dose of Pandemrix during the 2009 pandemic. We studied the effectiveness of the vaccine during the influenza seasons 2010-2011 and 2012-2013 in children hospitalized with virologically confirmed influenza. The season 2011-2012 was not included, since influenza A(H3N2) was the predominant circulating strain.
Methods: In a retrospective case-control study using a modified test-negative design we compared the percentage vaccinated with Pandemrix among children diagnosed with influenza A(H1N1)pdm09 (cases), with that of those diagnosed with influenza A(H3N2) or influenza B (controls) during the two seasons. We excluded children born after July 1, 2009, since only children who were 6 months of age or older received the pandemic vaccine in October-December 2009.
Results: During the 2010-2011 season, 3/16 (19%) of children diagnosed with influenza A(H1N1)pdm09, vs. 32/41 (78%) of those with influenza A(H3N2) or influenza B had been vaccinated with Pandemrix in 2009. The odds ratio, after adjustment for sex, age and underlying diseases, for becoming a case when vaccinated with Pandemrix was 0.083 (95%CI 0.014, 0.36), corresponding to a VE of 91.7%. During the season 2012-2013, there was no difference between the two groups; 59% of children diagnosed with influenza A(H3N2)/B and 60% of those with influenza A(H1N1)pdm09 had been vaccinated with Pandemrix in 2009.
Conclusion: The AS03 adjuvanted monovalent influenza A(H1N1) pdm09 vaccine (Pandemrix) was effective in preventing hospital admission for influenza A(H1N1)pdm09 in children during at least two seasons.
Keywords: Children; Effectiveness; Long term; Pandemic; Vaccination.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza.Vaccine. 2012 Aug 24;30(39):5699-702. doi: 10.1016/j.vaccine.2012.07.009. Epub 2012 Jul 20. Vaccine. 2012. PMID: 22819987
-
Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.Euro Surveill. 2016;21(7):pii=30139. doi: 10.2807/1560-7917.ES.2016.21.7.30139. Euro Surveill. 2016. PMID: 26924024
-
The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).Vaccine. 2015 Jun 4;33(24):2813-22. doi: 10.1016/j.vaccine.2015.04.012. Epub 2015 Apr 28. Vaccine. 2015. PMID: 25936723
-
Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis.Vaccine. 2017 Apr 11;35(16):1996-2006. doi: 10.1016/j.vaccine.2017.02.059. Epub 2017 Mar 14. Vaccine. 2017. PMID: 28302409 Review.
-
Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses.Vaccine. 2012 May 2;30(21):3209-22. doi: 10.1016/j.vaccine.2012.02.048. Epub 2012 Mar 2. Vaccine. 2012. PMID: 22387221 Review.
Cited by
-
Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting.Biologicals. 2019 Jul;60:1-7. doi: 10.1016/j.biologicals.2019.05.005. Epub 2019 May 23. Biologicals. 2019. PMID: 31130313 Free PMC article.
-
Influenza epidemiology among hospitalized children in Stockholm, Sweden 1998-2014.Vaccine. 2016 Jun 14;34(28):3298-302. doi: 10.1016/j.vaccine.2016.04.082. Epub 2016 May 4. Vaccine. 2016. PMID: 27155498 Free PMC article.
-
The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.Epidemiology. 2020 Jan;31(1):43-64. doi: 10.1097/EDE.0000000000001116. Epidemiology. 2020. PMID: 31609860 Free PMC article.
-
MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico.Hum Vaccin Immunother. 2018 Feb 1;14(2):386-395. doi: 10.1080/21645515.2017.1373227. Epub 2018 Jan 3. Hum Vaccin Immunother. 2018. PMID: 28925801 Free PMC article. Clinical Trial.
-
AS03- and MF59-Adjuvanted Influenza Vaccines in Children.Front Immunol. 2017 Dec 13;8:1760. doi: 10.3389/fimmu.2017.01760. eCollection 2017. Front Immunol. 2017. PMID: 29326687 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical